Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune ...

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of therapeutics ...

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical development progress, including the ...

The large molecule drug substance CDMO market is projected to grow at a CAGR of approximately 9% over the forecast period.

Several new guidance documents issued by the FDA are poised to significantly impact the rare disease development landscape.

Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of ...

Arvinas (NASDAQ:ARVN) gains attention within the nasdaq composite for its targeted protein degradation approach and institutional support.

As of Thursday, February 26, Maravai LifeSciences Holdings, Inc.’s MRVI share price has surged by 12.27%, which has investors questioning if this is right time to sell.

Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 ...

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical ...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...